This site is intended for healthcare professionals

FDA approves Kalydeco as first and only CFTR modulator to treat eligible infants with CF as early as four months of age.- Vertex

Read time: 1 mins
Last updated:16th Mar 2021
Published:26th Sep 2020
Condition: Cystic Fibrosis-CFTR
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest